A Microscale Human Liver Platform that Supports the Hepatic Stages of Plasmodium falciparum and vivax  by March, Sandra et al.
Cell Host & Microbe
ResourceA Microscale Human Liver Platform
that Supports the Hepatic Stages
of Plasmodium falciparum and vivax
Sandra March,1,4 Shengyong Ng,2 Soundarapandian Velmurugan,5 Ani Galstian,1,4 Jing Shan,1 David J. Logan,4
Anne E. Carpenter,4 David Thomas,4 B. Kim Lee Sim,5 Maria M. Mota,6 Stephen L. Hoffman,5
and Sangeeta N. Bhatia1,3,4,7,*
1Health Sciences and Technology, Institute for Medical Engineering and Science
2Department of Biological Engineering
3Howard Hughes Medical Institute, Koch Institute, and Electrical Engineering and Computer Science
Massachusetts Institute of Technology, Cambridge, MA 02139, USA
4Broad Institute, Cambridge, MA 02142, USA
5Sanaria Inc., Rockville, MD 20850, USA
6Unidade de Mala´ria, Instituto de Medicina Molecular, Universidade de Lisboa, 1649-028 Lisboa, Portugal
7Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA
*Correspondence: sbhatia@mit.edu
http://dx.doi.org/10.1016/j.chom.2013.06.005SUMMARY
The Plasmodium liver stage is an attractive target for
the development of antimalarial drugs and vaccines,
as it provides an opportunity to interrupt the life cycle
of the parasite at a critical early stage. However, tar-
geting the liver stage has been difficult. Undoubtedly,
a major barrier has been the lack of robust, reliable,
and reproducible in vitro liver-stage cultures. Here,
we establish the liver stages for both Plasmodium
falciparum and Plasmodium vivax in a microscale
human liver platform composed of cryopreserved,
micropatterned human primary hepatocytes sur-
rounded by supportive stromal cells. Using this sys-
tem, we have successfully recapitulated the full liver
stage of P. falciparum, including the release of in-
fected merozoites and infection of overlaid erythro-
cytes, as well as the establishment of small forms
in late liver stages of P. vivax. Finally, we validate
the potential of this platform as a tool for medium-
throughput antimalarial drug screening and vaccine
development.
INTRODUCTION
Despite major advances in the prevention and treatment of
malaria, this disease continues to be a major global health prob-
lem in human populations, with 250 million cases and nearly 1
million deaths every year (World Health Organization, 2010).
Malaria is transmitted by Plasmodium sporozoites after they
are injected by an infected mosquito. Uninucleate sporozoites
travel to and invade liver hepatocytes, where they mature and
multiply to form liver-stage schizonts. These schizonts eventu-
ally release pathogenic merozoites into the blood, where they
invade erythrocytes and lead to the major clinical symptoms,104 Cell Host & Microbe 14, 104–115, July 17, 2013 ª2013 Elsevier Isigns, and pathology of the disease. Human malaria is primarily
caused by four species of Plasmodium parasites. Plasmodium
falciparum (P. falciparum) is the most virulent and causes the
vastmajority of deaths.Plasmodium vivax (P. vivax) is less deadly
but highly disabling. Notably, some P. vivax sporozoites develop
into dormant hypnozoites, which remain in the liver and serve as
a P. vivax reservoir that gives rise to a chronic, relapsing infection
and causes significant added clinical and financial burden (Price
et al., 2007). Currently, there is a renewed interest and focus on
global malaria eradication, and it is now widely recognized that
existing tools are insufficient to meet this goal (Alonso et al.,
2011a, 2011b).
In particular, the clinical options that target the liver stages of
the parasite life cycle are inadequate. There is only one licensed
drug that eliminates hypnozoites, only a few drugs that target
liver-stage parasites, and no licensed malaria vaccines. This
problem has been exacerbated by the emergence of drug resis-
tance and the inability to treat some populations with prima-
quine, the only currently approved drug with antihypnozoite
activity (Wells et al., 2010). The Plasmodium liver stage is an
attractive therapeutic target for the development of both antima-
larial drugs and vaccines, as it provides an opportunity to inter-
rupt the life cycle of the parasite at a critical early stage. There-
fore, screening platforms that model the in vivo Plasmodium
liver stage could be used to advance the pipeline for antimalarial
drug development and to validate promising liver-stage vaccine
candidates (Epstein et al., 2011; Plowe et al., 2009).
Studies of rodent Plasmodium pathogens (P. berghei and
P. yoelii) have provided important insights, due in part to the
capacity to conduct both in vitro and in vivo assays (Hoffman
et al., 1989; Rodrigues et al., 2008; Silvie et al., 2007). Nonethe-
less, there are essential differences between the rodent and
human parasites, such as their antigenic variation and mecha-
nisms of host cell invasion (Carlton et al., 2002; McCutchan
et al., 1985). To date, our understanding of the liver stage of
human malaria, mainly P. falciparum and P. vivax, is based in
large part on the infection of human hepatoma cell lines (Chatto-
padhyay et al., 2010; Epstein et al., 2011; Hollingdale et al., 1983;nc.
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cell lines, however, display abnormal proliferation, aberrant
signaling, dysregulated gene expression, altered host responses
to infection, and inadequate CYP450 and drugmetabolism activ-
ity and thus do not accurately recapitulate human hepatocyte
biology. Furthermore, in situ observation of pathogen develop-
ment in liver cell lines is typically obscured after 6 days in culture,
due to the continued proliferation of infected cells (Yokoo et al.,
2004). Primary cultured human hepatocytes that exhibit more
physiologic human liver functions have been studied previously,
albeit less frequently than cell lines, and can support the devel-
opment of the liver forms of P. falciparum and P. vivax (Mazier
et al., 1984, 1985; Rodrigues et al., 2008; van Schaijk et al.,
2008; Yalaoui et al., 2008). Nonetheless, in the 25 years since
these findings were first published, primary hepatocyte systems
are rarely employed and difficult to translate to screening plat-
forms due to limited cell availability and challenges inmaintaining
their functional phenotype over extended periods of time in vitro
(Bhatia et al., 1999).
Two recent advances may help overcome the deficiencies of
existing in vitro liver models. First, several groups have devel-
oped methods and novel culture platforms that support the
maintenance of primary human hepatocytes (Bhatia et al.,
1999; Guguen-Guillouzo and Guillouzo, 2010; LeCluyse et al.,
2012). In particular, our group has developed a microliver plat-
form, which leverages bioengineering techniques to organize
primary human hepatocytes among supportive stromal cells
(Khetani and Bhatia, 2008). Hepatocytes in thesemicropatterned
cocultures (MPCCs) exhibit human-specific drug metabolism,
retain drug responsiveness and hepatic energy metabolism,
secrete of liver-specific proteins, polarize, and do not proliferate.
Importantly, the hepatocytes in MPCCs maintain a functional
phenotype for up to 4–6 weeks and are compatible with
medium-throughput drug screening methods and automated
data collection. This platform has been found to be more predic-
tive than existing in vitro liver models for generating and identi-
fying human drug metabolites and drug-induced liver toxicity
and supports the persistent replication of hepatitis C virus (Jones
et al., 2010; Ploss et al., 2010; Wang et al., 2010). Furthermore,
the availability of large cryopreserved lots of human primary
hepatocytes means that donor-dependent interexperimental
variability can be minimized. Nonetheless, reproducible access
to sporozoites is also critical to achieve a practical system. Cryo-
preservation of large batches of aseptic sporozoites has also
now been established for both P. vivax (Chattopadhyay et al.,
2010) and P. falciparum (Epstein et al., 2011) sporozoites.
In this resource report, we demonstrate the feasibility of inte-
grating cryopreserved human hepatocytes in MPCCs with cryo-
preserved P. falciparum and P. vivax sporozoites to form an
in vitro platform that supports the liver stages of human malaria
infection. This platform offers the potential for automation based
on several factors, including preselection of cryopreserved
human hepatocyte and sporozoite batches to standardize infec-
tion rate, a machine-learning algorithm that enables an auto-
mated imaging-based readout of immunofluorescent staining,
and the capacity to generate a positive Z factor in response to
drug exposure. The 96-well, medium-throughput format requires
fewer reagents (drugs, sporozoites) than larger footprint in vitro
assays, or than most in vivo assays, including humanized mouseCell Hmodels (Vaughan et al., 2012). Collectively, our data document
the development and characterization of a highly-reproducible,
medium-throughput microscale human liver platform that may
aid in the development of safe and efficacious antimalarial drugs
and liver-stage vaccines.
RESULTS
Functional Characterization of Micropatterned
Cocultures from Cryopreserved Primary Human
Hepatocytes
In order to establish an MPCC in vitro culture of primary human
hepatocytes (Figure 1A) suitable for Plasmodium infection, we
screened cryopreserved hepatocyes from several individual
patient donors to identify those that met the following criteria:
(1) selective adhesion to collagen type I; (2) maintenance of a
functional hepatocyte phenotype for up to 3 weeks as assessed
by albumin expression, urea production, and CYP450 activity;
and (3) expression of the previously identified Plasmodium host
entry factor, CD81 (Silvie et al., 2003). We identified eight donor
sources of cryopreserved human hepatocytes that were plate-
able on collagen I and displayed typical hepatocyte morphology,
including the presence of bile canaliculi (Figure S1 available
online). Seven of these sample sets demonstrated functional
capacity in culture, as quantified by their production of albumin
and urea, and also exhibited CYP450 activity for up to 3 weeks
(Figure 1B). We next quantified the expression of the host entry
factor CD81 on hepatocytes from each of the seven donors at
the day of infection. Four of these samples (donors 2, 3, 7, and 8)
expressed high levels of CD81 by immunofluorescence (IF)
(Figure 1D).
Infection of Primary Human Hepatocyte MPCCs with
P. falciparum
To test whether primary hepatocytes stabilized by culturing in
MPCCs can be infected with P. falciparum, we exposed MPCCs
to cryopreserved P. falciparum sporozoites (NF54) (Figures 2A
and 2B). We confirmed productive infection in all seven donors
by staining for HSP70 expression. However, a wide range
of infection rates were observed between lots (Figure 1C, left
panel). Specifically, at day 3 postinfection, the number of
HSP70-positive, P. falciparum-infected hepatocytes was much
higher in samples from donors 7 and 8 relative to the other tested
lots. Hepatocytes from donors 7 and 8 were selected for further
characterization of themodel. We also examined the susceptibil-
ity of the same donor samples to productive infection by two
different rodent species of Plasmodium. As shown in Figure 1C
(middle panel), donors 7 and 8 also exhibit the highest levels of
P. yoelii infection. However, this correlation was not observed
in P. berghei (Figure 1C, right panel). Overall, infection
with P. berghei was higher compared with P. falciparum
and P. yoelii, with donor 1 showing slightly higher infection with
P. berghei than the other donors. Interestingly, high CD81
expression was necessary, but not sufficient, to support robust
infection by P. falciparum (Figures 1C and 1D). We next evalu-
ated three different batches of cryopreserved P. falciparum
sporozoites. As seen in Figure 1F, this experiment confirmed
productive infection using sporozoites from three cryopreserved
batches. However, infection efficiencies varied across batches.ost & Microbe 14, 104–115, July 17, 2013 ª2013 Elsevier Inc. 105
Figure 1. Functional Characterization of Cryopreserved Human Hepatocytes in Micropatterned Cocultures and Cryopreserved Plasmodium
falciparum Sporozoites
(A) Morphology of primary human hepatocytes in micropatterned cocultures (left; hepatocytes, red and fibroblasts, green). Representative coculture of
hepatocytes with (middle) and without (right) fibroblasts 18 days postseeding.
(B) Albumin secretion, urea synthesis, and CYP450 activity in MPCCs of different donors. Red dashed lines indicate the average level observed in 6-day
hepatocyte monocultures (SD = 0.9, 5.4, and 0.06 for the left, middle, and right panels, respectively).
(C) P. falciparum, P. yoelii, and P. berghei infection across donors.
(legend continued on next page)
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selected for further characterization of the model. Importantly,
we observed higher infection rates when hepatocytes were
cultured in the MPCC format as opposed to standard, unpat-
terned (randomly distributed) monocultures (Figure 1E, Hep
Random). MPCCs remained susceptible to P. falciparum infec-
tion for many weeks after they were patterned; however, infec-
tion rates are optimal at day 2 after patterning (data not shown).
Recapitulation of the Entire P. falciparum Liver Stage in
MPCCs
Having established thatP. falciparum can infectMPCCs, we next
sought to establish whether the entire liver stage could be repro-
duced in vitro. The viability of the cryopreserved P. falciparum
sporozoites was evaluated by assessing their gliding motility
(Figure 2C) and by their capacity to traverse cells using a cell-
wounding assay (Mota et al., 2001). On average, the addition
of 37,000 motile cryopreserved P. falciparum sporozoites
to 10,000 patterned hepatocytes resulted in 3% rhodamine-
positive traversed cells (Figure 2D). To quantify the ability
of the P. falciparum sporozoites to invade hepatocytes,
P. falciparum-treated MPCCs were fixed 3 hr postinfection
(Re´nia et al., 1988). On average, 10% of hepatocytes contained
intracellular cryopreserved P. falciparum sporozoites (Figure 2E).
The human hepatocyte infection rate, based on the percentage
of cells containing HSP70-expressing parasites at day 3 postin-
fection, was 0.2% (Figure 2J). Notably, at this same time point,
fresh sporozoites achieved infection rates that were 7- to
13-fold higher (Figure 5A). Representative images of the
HSP70-expressing parasites at day 3 and day 5 are shown in
Figures 2F and 2G.
The maturation of parasites derived from cryopreserved
P. falciparumwas assessed using three parameters: (1) immuno-
staining of the infected cultures with antibodies against two
proteins first expressed during late liver stages, PfEBA-175
(P. falciparum erythrocyte-binding antigen, 175 kDa) and
PfMSP-1 (merozoite surface protein 1), which indicate full devel-
opment of the respective schizonts inside the hepatocytes into
merozoites; (2) the size of HSP70-expressing schizonts relative
to previous reports of P. falciparum schizont size during liver-
stage development; and (3) the progression rate, calculated as
the percentage of schizont-bearing cells at day 6 relative to
day 3. At day 5 postinfection, cryopreserved sporozoites ex-
press both PfEBA-175 and PfMSP-1 (Figure 3C). The parasites
we observed were similar in size to what has been reported in
other in vitro settings (10–15 mm at day 5) (Mazier et al.,
1985; van Schaijk et al., 2008) but smaller than those reported
in vivo (Shortt et al., 1951; Shortt and Garnham, 1948; Vaughan
et al., 2012) (Figures 2L and 3B). Importantly, we demonstrated
that the rate at which parasites progressed to the schizont stage
between day 3 and day 6 postinfection was higher in infected
MPCCs (33%) relative to the commonly used hepatoma line
HC04 (14%) (Figure 2K).(D) Representative CD81 immunofluorescence staining at day 4 postseeding (le
(right; n.d., not detected).
(E) P. falciparum infection in hepatocyte monocultures, micropattern (MP), or rand
were plated in each case.
(F) Levels of infection by three sporozoite batches in a single hepatocyte donor.
Cell HFinally, to demonstrate that hepatic schizonts derived from
cryopreserved P. falciparum sporozoites could achieve full
maturity and release infective merozoites, red blood cells
(RBCs) were added to the hepatocyte cultures at day 6 postin-
fection. After 10 days, Giemsa staining revealed infection of
erythrocytes by P. falciparum merozoites (Figures 2H and 2I).
Assessing Progression of Attenuated P. falciparum for
Vaccine Applications
The ability of the MPCCs to recapitulate the entire liver stage of
P. falciparum in vitro highlights the potential to use this platform
to study the biology of P. falciparum-infected hepatocytes. For
example, this capability should enable the assessment of candi-
date pre-erythrocyte malarial vaccines that are based on live-
attenuated parasites (Annoura et al., 2012; Epstein et al., 2011;
Mueller et al., 2005; van Schaijk et al., 2008).
To illustrate the potential use of MPCCs in vaccine develop-
ment, we compared the infection capacity of a pre-erythrocytic
malaria vaccine candidate comprised of cryopreserved, live-
attenuated P. falciparum sporozoites to that of cryopreserved
nonattenuated (wild-type) P. falciparum sporozoites. Entry of
the attenuated parasites was evaluated relative to the function
of nonattenuated parasites. As seen in Figure 3A, entry by both
groups of parasites was similar. Late liver-stage development
was evaluated at day 5 postinfection. Immunofluorescence
staining with EBA-175 and MSP-1 antibodies detected mature
schizonts only in MPCCs infected with the nonattenuated sporo-
zoites, whereas MPCCs infected with the live-attenuated sporo-
zoites were positive only for the early liver-stage antigen, LSA-1
(Figure 3C). As expected, schizonts that were established by the
nonattenuated sporozoites were larger than the immature forms
established by the attenuated sporozoites where the hepatic-
stage development is arrested. Figure 3B shows a scatter plot
of the range of exoerythrocytic form (EEF) sizes generated by
each group.
Development of a Semiautomated, Medium-Throughput
Platform for Antimalarial Applications
We next explored the utility of the MPCCs as a potential antima-
larial drug screening platform. The hepatocyte serves as both
the site of antimalarial drug metabolism (or bioactivation) and
the host for the parasite. Thus, phenotypic stability of the
hepatocyte and a full drug metabolism repertoire has the
potential to capture a full range of drug responses such as
efficacy, drug-drug interaction, and toxicity (Ploss et al., 2010).
MPCCs were established in a 96-well format, infected with
P. falciparum, and treated with the canonical malaria drug,
primaquine. The impact of the drug was evaluated based on its
ability to reduce parasite infection relative to control cultures in
a multiday dose. As seen in Figures 4A and 4B, the half maximal
inhibitory concentration (IC50) for primaquine was approximately
1 mM for P. falciparum during 3 days in culture. The IC50 for
P. falciparum in the MPCC was lower compared to the IC50ft). Heatmap indicates relative CD81 expression per donor as measured by IF
omly distributed (Random) relative to infection in MPCCs. 10,000 hepatocytes
Error bars represent SD. See also Figure S1.
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Figure 2. Liver-Stage Recapitulation in Primary Human Hepatocyte MPCCs
(A) Schematic of P. falciparum infection assay.
(B) Typical morphology of primary human hepatocytes in MPCCs (hepatocytes, red; fibroblasts, green).
(C) Representative image of P. falciparum sporozoites gliding. CSP immunostaining was used to visualize trails. Quantification based on the average fraction of
sporozoites that perform at least one circle.
(legend continued on next page)
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Figure 3. Comparison of Live-Attenuated versus Wild-Type
Parasites for Candidate Vaccine Evaluation
(A) Number of infected hepatocytes observed after wild-type (nonattenuated)
and attenuated cryopreserved sporozoite infection.
(B) Size distribution of wild-type and attenuated parasites in MPCCs after
5 days of culture.
(C) Representative images of parasites at day 5 postinfection. Wild-type par-
asites are identified by anti-MSP-1 and anti-EBA-175 staining. Attenuated
parasites are identified by anti-LSA-1 staining. Nuclei are visualized with DAPI
(blue). Scale bar = 10 mm. Error bars represent SEM.
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line HC04 (Figures 4A and 4B). Primaquine is known to require
bioactivation in the liver in order to produce active daughter
metabolites that mediate drug action (Pybus et al., 2012).
Thus, the clearance of the parent compound can be used as a
proxy for the level of bioactivation in culture. We monitored
depletion of primaquine in MPCCs, patterned monocultures of
primary hepatocytes only (Hep MP), and the HC04 cell line
over 2 days by high-performance liquid chromatography and
found that MPCCs most efficiently cleared primaquine over
this time frame (Figure 4C). We next compared the expression
level of 83 human-specific drug metabolism genes in order to
assess whether the observed macroscopic differences in parent
compound depletion correlates with the drug metabolism repor-
toire of these model systems. In general, the bulk of hepatocyte
drug metabolism genes were expressed at higher levels in the
MPCCs (Figure 4E). Of the three major enzymes involved with
primaquine metabolism, two of the three were expressed at(D) Cell traversal ability of P. falciparum sporozoites as visualized by dextran-po
(E) Representative double immunofluorescence stain (anti-PfCSP, both before an
intracellular sporozoites are labeled with yellow and red, respectively. Nuclei are
(F and G) Representative images of P. falciparum in human primary hepatocytes
staining (red).
(H and I) Infection of human RBCs by merozoites released from infected liver-stag
and the trophozoite stage (I).
(J) Infection rates using MPCC primary human hepatocytes or HC04 hepatoma c
(K) Progression rate from day 3 to day 6 in MPCC and HC04 calculated as infec
sporozoites).
(L) Schizont size distribution at days 3, 4.5, 6, and 7. Scale bar = 5 mm (F–I), 10 m
Cell Hhigher levels in MPCC than the other systems. In particular,
monoamine oxidase A (MAO-A), which is thought to account
for over 75% of primaquine metabolism, was expressed at a
level 4-fold higher than hepatoma cell lines, suggesting that
the platform may offer a more predictive system with which to
assay candidate drug performance, including studies of mecha-
nisms of action.
Next, to further adapt the microliver platform for medium-
throughput screens, we characterized several critical parame-
ters. As seen in Figures 5A and 5B, we found that day-to-day
variability of hepatocyte infection using the same batch of cryo-
preserved sporozoites could be minimized (coefficient of varia-
tion [CV] = 10%) when compared to the range of infection rates
obtained using three independent batches of fresh sporozoites
(CV = 42%). Next, a positive Z factor (Z0 > 0), which indicates
confidence in separating two normally distributed populations,
was obtained when primaquine-treated wells (10 mM) were
compared to control cultures (Figure 5C). In addition, the repro-
ducibility of a phenotypic assay was assessed by establishing
consistent dose-dependent inhibitory effects of two different
drugs at three different concentrations in two independent
experiments (atovaquone and primaquine) (Figure 5D). Further-
more, the magnitude of the inhibitory impact of primaquine
was consistent across two independent human hepatocyte
donors (Figure S2). Finally, we established and validated an
automated image analysis readout using this platform, following
the infection of MPCCs with two different doses of sporozoites.
As shown in Figures 5E andS3, the number of parasites detected
by automated image acquisition and analysis closely matches
the counts obtained using conventional manual fluorescence
microscopy.Infection of MPCCs with Plasmodium vivax
Plasmodium vivax differs from P. falciparum in several important
ways. A key feature ofP. vivax that underlies its persistence in the
population is that the liver acts as a reservoir for dormant hypno-
zoites or small forms (Cogswell, 1992; Krotoski et al., 1982).
These hypnozoites can reactivate after weeks, months, or even
years, depending on the strain of P. vivax (Dao et al., 2007;
Durante Mangoni et al., 2003; Garnham et al., 1975). However,
due to a lack of model systems available to investigate this
elusive organism, the biology of the dormant form of P. vivax is
underexplored.
Based on our ability to establish the liver stage of
P. falciparum in MPCCs and maintain the hepatocyte phenotype
for 4–6 weeks and the observation that some strains of P. vivax
can reactivate over a similar timescale, we next explored thesitive staining of primary human hepatocytes.
d after cell permeablization) of P. falciparum-infected MPCCs. Extracellular and
visible with blue DAPI stain.
at days 3 (F) and 5 (G) postinfection. Parasites are identified by anti-PfHSP70
e culture. Representative images of Giemsa-stained RBCs in the ring stage (H)
ells, calculated based on the plated number of sporozoites or hepatocytes.
tion rate of day 6O infection rate of day 3 3 100 (based on hepatocytes and
m (C and E), or 100 mm (D). Error bars represent SEM.
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Figure 4. Utility of Medium-Throughput Human Hepatocyte Platform to Identify Lead Compounds
(A) Primaquine treatment of MPCCs or HC04 infected with fresh or cryopreserved sporozoites.
(B) IC50 of primaquine in MPCCs versus HC04 (p = 0.0002 by one-way ANOVA; ***p < 0.001 by Tukey’s multiple comparison test).
(C) Primaquine metabolism by HC04, MPCCs, and patterned monocultures of primary human hepatocytes (Hep MP) quantified by liquid chromatography-
tandem mass spectrometry (LC-MS/MS).
(D) Relative expression of three putative metabolism genes implicated in primaquine metabolism.
(E) Heatmap displays of LMA-Luminex analysis for 83 human-specific drug metabolism genes. Columns represent triplicate loadings of RNA extracted from
HEPG2, HC04, MPCC, and Hep MP. Gene expression relative to average of control gene transferrin, and heatmaps are row normalized. Error bars represent
SEM. See also Figure S2.
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Figure 5. Adapting the Format to Drug
Screening
(A) Interexperimental variability measured by the
coefficient of variation (CV) and infection rate using
fresh and cryopreserved sporozoites from three
different batches.
(B) Interexperimental variability measured by the
coefficient of variation (CV) and infection rate using
cryopreserved sporozoites from the same batch.
(C) Heatmap indicating levels of infection (green,
highest EEF numbers; red, lowest EEF numbers)
observed in seven representative control or pri-
maquine-treated wells. Comparison yields posi-
tive Z factor.
(D) P. falciparum infection with primaquine or
atovaquone in two independent experiments
performed on different days.
(E) P. falciparum infection in MPCCs following two
doses of fresh sporozoites determined by manual
counts (indicated by M) or image analysis auto-
mation (indicated by A). Error bars represent SEM.
See also Figure S3.
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over time. As for the P. falciparum experiments, the viability of
the cryopreserved P. vivax sporozoites was evaluated by as-
sessing their gliding motility prior to each experiment (Figure 6A).
We explored several strains of P. vivax including Chesson, a
strain known to efficiently form dormant forms and reactivate
at shorter timescales (Hollingdale et al., 1986; Krotoski et al.,
1986). Cultures were infected and then fixed at various time
points and stained for circumsporozoite protein (CSP). Using
immunofluorescence microscopy, we analyzed the size distri-
bution and localization of the P. vivax forms over a 3-week
period. We readily observed P. vivax liver forms in MPCC,
including mature, liver-stage schizonts larger than 20 mm found
at day 6 postinfection (Figures 6C, 6B, S4A, and S4B). In addi-
tion, a population of smaller P. vivax CSP (PvCSP)-positive
forms (<5 mM) was detected within MPCCs at all time points,
particularly identifiable at 6 and 21 days postinfection (Figures
6A, 6B, and S4A–S4C). The infection efficiency, based on the
percentage of hepatocytes containing large and small PvCSP-
positive forms at day 6 postinfection, was 0.013% and 2%,
respectively (Figure S4D). Similar numbers of small forms
were observed up to day 21 (data not shown). Importantly,
85% of the small forms observed were intracellular, based on
immunostaining performed before and after permeabilization
(Figure S4C). In contrast, cultures infected with P. falciparum
contained very few small forms after 15 days in culture, and
those were predominantly extracellular (Figure S4E). These
P. vivax small forms may represent the dormant hypnozoite
stage of the parasite life cycle, which is responsible for clinical
relapses in P. vivaxmalaria patients; however, further character-
ization will be required to substantiate this hypothesis. Both
small and large forms were observed when other strains of freshCell Host & Microbe 14, 104–and frozen P. vivax sporozoites were
examined (Figure S4A and data not
shown). Finally, we demonstrated that
the MPCC system can support matura-
tion of hepatic P. vivax schizonts, basedon the detection of the late-stage antigen PvMSP-1 at day 12
postinfection (Figure S4B).
DISCUSSION
In this report, we describe an in vitro cell-based platform that
recapitulates the human liver stage of P. falciparum and
P. vivax infection. Although some attempts to infect cryopre-
served human primary hepatocytes have been described in the
past (Meis et al., 1985; Silvie et al., 2004), this source of hepato-
cytes has not been routinely adopted by the field to date. The
advantages of screening individual donor-derived, cryopre-
served hepatocytes is paralleled by the successful production
of purified, vialed, cryopreserved sporozoites (Chattopadhyay
et al., 2010; Epstein et al., 2011; Hoffman et al., 2010). These cry-
opreserved resources overcome the donor-to-donor variability
seen in primary cultured human hepatocyes as well as infectivity
rate variability introduced by different batches of mosquitoes
or sporozoites. In addition, the use of cryopreserved compo-
nents in this platform allows for a reliable source of reagents
for use in longitudinal experiments, including screening and
subsequent validation. Furthermore, since cell culture of
patterned hepatocytes using the MPCC platform can maintain
individual patient samples for 4 and 6weeks (Khetani and Bhatia,
2008), it is feasible to perform long-term monitoring of both
liver- and blood-stage Plasmodium infections, analyze genetic
changes acquired inside Anopheles mosquitoes, assess the
safety of attenuated sporozoite vaccine candidates, and charac-
terize P. vivax hypnozoites in vitro using this system. Notably,
development of vaccines and drugs against this stage of
P. vivax has been identified as a critically important goal for
research to eradicate malaria (Alonso et al., 2011a, 2011b).115, July 17, 2013 ª2013 Elsevier Inc. 111
Figure 6. Infection with Plasmodium vivax
(A) Representative image of PvCSP-stained
P. vivax (Chesson) sporozoites gliding.
(B) Representative images of PvCSP-positive
parasites over time. Scale bar = 10 mm.
(C) Size distribution of P. vivax parasites in MPCCs
over time. Red, all observed parasites bigger than
5 mm; black, 20 representative forms smaller than
5 mm. See also Figure S4.
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vaccines continue to underperform in clinical trials, and signifi-
cant ‘‘blood breakthrough’’ of presumably attenuated parasites
formulations has been observed (Annoura et al., 2012).
In our experience with disease modeling of drug-induced liver
injury and hepatitis C infection, establishing platforms that better
reflect host biology is an important first step to determining
where existing model systems were lacking (e.g., P450 activity
and interferon signaling, respectively). In this case, we have
already observed three advantages over in vitro hepatoma cul-
tures: (1) sporozoites appear to progress through the parasite
life cyclemore efficiently inMPCCs relative to infected hepatoma
cells, offering the potential to improve studies of drugs and
sporozoite attenuation strategies that act in the second half of
the liver life cycle; (2) MPCCs are able to predict differences in
infection rates of sporozoites in vivo that result from cryopreser-
vation, likely reflecting the presence of critical host factors that
are altered in hepatoma cells (Albuquerque et al., 2009; Epipha-
nio et al., 2008; Prudeˆncio et al., 2008; Rodrigues et al., 2008;112 Cell Host & Microbe 14, 104–115, July 17, 2013 ª2013 Elsevier Inc.Silvie et al., 2003); and (3) MPCCs fabri-
cated from different human hepatocyte
donors enable direct comparison of host
factors that impact entry of different
sporozoite species and strains (e.g.,
CD81 in P. yoeli, P. berghei, and
P. falciparum), whereas hepatoma cells
are typically limited to one or very few
donor genotypes. We demonstrated that
maintenance of hepatocyte function and
expression of the host entry factor CD81
(Silvie et al., 2003) were necessary, but
not sufficient, to obtain adequate levels
of infection by P. falciparum. This finding
suggests the existence of molecular dif-
ferences among donors that determine
their permissiveness to Plasmodium
infection. Furthermore, most antimalarial
drug development leads identified in
RBC-based high-throughput screens do
not require metabolic activation. Thus, in
such cases, screening via the MPCC
format might yield the same, higher, or
lower IC50 predictions, should the candi-
date compound be cleared rapidly or bio-
activated via metabolic pathways (Gamo
et al., 2010; Guiguemde et al., 2010).
The infection rates reported in this
study using cryopreserved sporozoitesare comparable or higher than those previously documented
with fresh sporozoites, and they are an additional 10-fold
higher when fresh sporozoites are used in this platform (Mazier
et al., 1984, 1985; Sattabongkot et al., 2006; van Schaijk et al.,
2008). The infection rates of hepatocytes in MPCCs are similar
in comparison to the infection rates recently reported in HC04
cells, which range from 0.4% to 0.06% (Epstein et al., 2011; Sat-
tabongkot et al., 2006). However, in our system, the progression
rate from one stage of the life cycle to the other was much higher
than in HC04, offering the potential for studying later stages of
the liver life cycle more efficiently. Nonetheless, our MPCC infec-
tion rates remain low relative to those recorded in in vivo settings
(Shortt et al., 1951; Shortt and Garnham, 1948). Experiments
done in mice with P. yoelii (Conteh et al., 2010) and nonhuman
primates with P. knowlesi (Jiang et al., 2009) have demonstrated
that intravenous inoculation of only a few noncryopreserved
sporozoites (10 sporozoites [SPZ]) can lead to a productive
malaria infection that results in detectable parasitemia in the
blood stage. Varying hypotheses have been put forward to
Cell Host & Microbe
Malaria Liver Stage in a Microscale Human Platformexplain the discrepancy between model systems. For example,
our in vitro systems do not provide the host hepatocytes with
potentially necessary, physiologically relevant cellular compo-
nents such as Kupffer cells or sinusoidal endothelial cells.
Further, the MPCC platform conformational cues may be impor-
tant for EEF growth (e.g., two-dimensional versus three-dimen-
sional). These hypotheses will be explored further.
In conclusion, the ability to support the liver stages of
P. falciparum and P. vivax parasites in a medium-throughput
format offers promise to improve our fundamental understand-
ing of the liver stages of human malaria as well as accelerate
the development of drugs and vaccines to aid in its eradication.
EXPERIMENTAL PROCEDURES
Micropatterned Cocultures
12 mm coverslips that were placed into tissue culture polystyrene 24-well
plates or glass-bottomed 96-well plates were coated homogenously with
rat tail type I collagen (50 mg/ml) and subjected to soft lithographic
techniques (Ploss et al., 2010) to pattern the collagen into microdomains
(islands of 500 mm) that mediate selective hepatocyte adhesion. To create
MPCCs, cryopreserved primary human hepatocytes were pelleted by
centrifugation at 100 3 g for 6 min at 4C, assessed for viability using
trypan blue exclusion (typically 70%–90%), and then seeded on collagen-
micropatterned plates. The cells were washed with medium 2–3 hr later
and replaced with human hepatocyte culture medium. 3T3-J2 murine
embryonic fibroblasts were seeded (40,000 cells per well of a 24-well plate
and 10,000 cells per well of a 96-well plate) in fibroblast medium 3 days
later. Fibroblast medium was replaced with human hepatocyte medium
24 hr after fibroblast seeding and subsequently replaced daily (Khetani
and Bhatia, 2008).
P. falciparum and P. vivax Sporozoites
Mosquitoes were fed on Pf- and Pv-infected blood as previously described
(Chattopadhyay et al., 2010; Epstein et al., 2011). Briefly, P. falciparum and
P. vivax sporozoites were extracted from infected mosquitoes by dissection
of their salivary glands and passing the glands back and forth through a 26G
needle fitted to a 1 ml syringe. Following extraction, sporozoites were purified
from mosquito salivary gland material contamination and cryopreserved
in liquid nitrogen vapor phase (LNVP) (Epstein et al., 2011; Hoffman et al.,
2010). Live-attenuated P. falciparum sporozoites were attenuated by expo-
sure of PfSPZ-infected mosquitoes to 150 Gy (Epstein et al., 2011; Hoffman
et al., 2010).
Infection of MPCCs with P. falciparum and P. vivax
Typically, infection of MPCCs is conducted 2 days after hepatocyte seeding,
but it can also be initiated after longer culture periods. Cryovials containing
P. falciparum or P. vivax were warmed for 30 s at 37C, 200 ml of human
hepatocyte medium was added, and the cryovials were centrifuged for
2 min at 14,000 3 g. Next, 200 ml of the supernatant was aspirated, and
the sporozoite pellet was resuspended and diluted accordingly. Each well
was infected with a ratio of 3:1 (infective sporozoites:hepatocytes). After
incubation at 37C and 5% CO2 for 3 hr, the wells were washed once, and
fresh medium was added. Medium was replaced daily. Samples were fixed
on days 3 and 5 postinfection with P. falciparum, and days 3, 6, 12, and
21 postinfection with P. vivax.
Cell Wounding and Membrane Repair Assay
Sporozoite migration through cells can be quantified by the detection of sporo-
zoite-wounded hepatocytes using a cell-impermeant fluorescent tracer
macromolecule as previously described (Mota et al., 2001). Briefly, MPCCs
were infected with P. falciparum in the presence of 1 mg/ml of 10,000 Da
tetramethylrhodamine-dextran (lysine-fixable) (Sigma). At 3 hr postinfection,
MPCCs were washed thrice with PBS, fixed with 1% paraformaldehyde at
room temperature for 20 min, and mounted on glass slides. Migration ofCell Hsporozoites through cells is quantified by the number of dextran-positive
hepatocytes per island.
Double-Staining Assay for Sporozoite Entry
At 3 hr postinfection, primary human hepatocytes or MPCCs were fixed and
stained using a double-staining protocol as previously described (Re´nia
et al., 1988). Briefly, to label extracellular sporozoites, the samples were fixed
with 4% paraformaldehyde for 10 min at room temperature, blocked with 2%
BSA in PBS, incubated with a primary mouse anti-PfCSP (1:100, Sanaria) (Nar-
din et al., 1982), washed thrice in PBS, and incubated with a secondary goat
anti-mouse Alexa Fluor 488 conjugate. This was followed by permeabilization
with 20C methanol for 10 min at 4C, incubation with the same primary
mouse anti-PfCSP, washing thrice with PBS, and incubation with a secondary
goat anti-mouse Alexa Fluor 594 conjugate. This second step labels both intra-
cellular and extracellular sporozoites. In case of MPCCs, the samples were
counterstained with Hoechst and mounted on glass slides as described
above. The number of invaded sporozoites (only green) in primary human
hepatocytes was counted using Acumen Explorer.
Gliding Assay
Motility of cryopreserved sporozoites was determined in each batch to define
the number of infective sporozoites. Sporozoite gliding was evaluated with
20,000 sporozoites for 40 min in complete Dulbecco’s modified Eagle’s
medium (DMEM), at 37C on glass coverslips covered with anti-CSP mono-
clonal antibody (clone 2A10 for P. falciparum and 210 clone NSV3 for
P. vivax). Sporozoites were subsequently fixed in 4% paraformaldehyde
(PFA) for 10 min and stained with anti-CSP. The percentage of sporozoites
associated with CSP trails was visualized by fluorescence microscopy. Quan-
tification was performed by counting the average percentage of sporozoites
that perform at least one circle.
Primaquine Treatment of P. falciparum EEFs in MPCCs
Infected MPCCs were incubated with media containing primaquine diphos-
phate (Sigma) ranging from 0.5–20 mM. Fresh primaquine-containing medium
was added daily until the samples were fixed at days 3 and 5 postinfection.
RNA Isolation and LMA-Luminex Analysis
Total RNA from three wells per condition was purified using TRIzol (Invitrogen)
and RNeasy Mini kit (QIAGEN) and pooled for analysis. LMA-Luminex proce-
dures and probes are previously described (Chen et al., 2011). Briefly, data
for triplicate loadings, expressed in mean fluorescent intensity of at least
100 beads per sample, were scaled to the human transferrin gene and row
normalized for heatmap representation using GenePattern open-source
software (Broad Institute).
Image Automation
Images of 96-well plates were acquired using high-content screening micro-
scopes (ImageXpress Micro XL, Molecular Device) and then analyzed by Cell-
Profiler and CellProfiler Analyst (Broad Institute) (Carpenter et al., 2006; Jones
et al., 2008). Parasites were visualized through immunofluorescent staining of
the HSP70 protein and can be distinguished from imaging artifacts by their
proximity to a hepatocyte nucleus (within 30 pixels) and lack of autofluores-
cence (no signal in unlabeled channels). We developed an automated image
analysis pipeline to identify every infection in every image and measure hun-
dreds of features (e.g., shape, area, texture) of each parasite. These features
are then used to train machine learning algorithms to identify and count the
number of parasites in each image using CellProfiler Analyst.
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